Toll-like receptor 4 - myeloid differentiation factor 2 complex (TLR4-MD-2)

The Toll-like receptor 4 - myeloid differentiation factor 2 (TLR4-MD-2) complex is a critical pattern recognition receptor of the innate immune system, primarily responsible for detecting lipopolysaccharide (LPS) from Gram-negative bacteria [1, 10]. This receptor complex consists of the transmembrane protein TLR4 and the extracellular adaptor protein MD-2, which contains a large hydrophobic pocket essential for binding the lipid A portion of LPS [1, 3]. Upon ligand engagement, the complex undergoes a conformational change that promotes the formation of a symmetrical (TLR4-MD-2-LPS)2 homodimer, initiating intracellular signaling through MyD88-dependent and TRIF-dependent pathways [1, 10, 14]. These pathways lead to the activation of transcription factors like NF-kappaB and IRF3, resulting in the production of pro-inflammatory cytokines and type I interferons [1, 5]. Dysregulation of TLR4-MD-2 signaling is a major driver of pathological conditions such as sepsis, chronic inflammatory diseases, and certain cancers [1, 11, 16]. Therapeutic interventions targeting the MD-2 binding pocket include antagonists like Eritoran, designed to prevent endotoxic shock by blocking LPS binding and receptor dimerization [1, 2]. Additionally, TLR4-MD-2 agonists such as monophosphoryl lipid A (MPLA) are effectively used as vaccine adjuvants to stimulate robust immune responses [1, 12].

Other names

TLR4/MD-2 complexCD284/LY96 complexLPS receptor complexToll-like receptor 4 - lymphocyte antigen 96 complexMyeloid differentiation factor 2 - Toll-like receptor 4 complex

Competitive antagonism of the MD-2 hydrophobic pocket to prevent lipopolysaccharide binding and subsequent receptor dimerization; or agonistic activation to stimulate innate immunity [1, 3, 10].